List of Medicines Access Programs (MAPs) and their respective characteristics in Australia and New Zealand in 2014-15. in Australia Number Patient NZ MAP MAP Brand (Aus) Indications of TGA Medicine of PBS status Medsafe name and/or covered patients status centres status Australia NZ New enrolled (AUD) schedule Zealand (NZ) Metastatic outside Aus and March Listed June Listed Abiraterone Zytiga® 6 No prostate 17 None funding no funding NZ 2012 Aug 2013 2013 May 2015 cancer restrictions Epidermal Growth Factor no Receptor Nov no Afatanib Aus 7 Yes 21 None rejected no funding no funding positive 2013 registration July 2015 non-small cell lung cancer In combination with based in eligible no patients with PBAC - Feb Dec registration Aflibercept Zaltrap® Aus 3 Yes metastatic 7 None no funding no funding 2012 2014 , no colorectal July 2013 funding cancer (mCRC) previously treated with an
List of Medicines Access Programs (MAPs) and their respective characteristics in Australia and New Zealand in 2014-15. Medicine Brand name in Australia (Aus) and/or New Zealand (NZ) of centres status Indications covered Number of patients enrolled Patient (AUD) TGA status PBS status MAP Australia Medsafe NZ schedule MAP NZ Abiraterone Zytiga® Aus and NZ 6 No Metastatic prostate cancer 17 None March 2012 Listed Aug 2013 outside funding restrictions June 2013 Listed May 2015 no funding Afatanib Aus 7 Yes Epidermal Growth Factor Receptor positive non-small cell lung cancer 21 None Nov 2013 July 2015 no funding no registration no funding no registration Aflibercept Zaltrap® Aus 3 Yes In combination with based in eligible patients with metastatic colorectal cancer (mCRC) previously treated with an 7 None Feb 2012 PBAC July 2013 no funding Dec 2014 no funding no no funding , rejected -
1-s2.0-S0168851017303457-mmc1.docx